As of Q4'25, Pfizer’s PEG Ratio (5yr expected) stands at 0.15, reflecting a modest recovery from the previous quarter and marking a positive shift compared to the negative values observed earlier in 2024. This latest data point suggests a stabilization after a period of significant volatility. Over the period from Q1'23 to Q4'25, the PEG Ratio exhibited considerable fluctuations, including a sharp decline to -16.78 in Q2'24, followed by a rapid rebound and ongoing variability. The ratio moved between positive and negative territory, indicating inconsistent growth expectations relative to earnings. The most notable inflection occurred in Q2'24 with the dramatic negative spike, but subsequent quarters show a return toward more normalized levels, suggesting improved outlook and reduced volatility by the end of 2025.